153 related articles for article (PubMed ID: 22449944)
1. Advances in the use of multimarker panels for renal risk stratification.
Weekley CC; Peralta CA
Curr Opin Nephrol Hypertens; 2012 May; 21(3):301-8. PubMed ID: 22449944
[TBL] [Abstract][Full Text] [Related]
2. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes.
Waheed S; Matsushita K; Astor BC; Hoogeveen RC; Ballantyne C; Coresh J
Clin J Am Soc Nephrol; 2013 Mar; 8(3):434-42. PubMed ID: 23258794
[TBL] [Abstract][Full Text] [Related]
3. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.
Peralta CA; Shlipak MG; Judd S; Cushman M; McClellan W; Zakai NA; Safford MM; Zhang X; Muntner P; Warnock D
JAMA; 2011 Apr; 305(15):1545-52. PubMed ID: 21482744
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.
Isakova T
Curr Opin Nephrol Hypertens; 2012 May; 21(3):334-40. PubMed ID: 22487610
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in native and transplant kidneys: opportunities to improve prediction of outcomes in chronic kidney disease.
De Serres SA; Varghese JC; Levin A
Curr Opin Nephrol Hypertens; 2012 Nov; 21(6):619-27. PubMed ID: 22914685
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of CKD patients receiving outpatient nephrology care in Italy.
De Nicola L; Chiodini P; Zoccali C; Borrelli S; Cianciaruso B; Di Iorio B; Santoro D; Giancaspro V; Abaterusso C; Gallo C; Conte G; Minutolo R;
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2421-8. PubMed ID: 21817127
[TBL] [Abstract][Full Text] [Related]
7. Strengths and weaknesses of renal markers as risk factors and surrogate markers.
Johnson KR
Kidney Int; 2011 Jun; 79(12):1272-4. PubMed ID: 21625257
[TBL] [Abstract][Full Text] [Related]
8. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.
Astor BC; Shafi T; Hoogeveen RC; Matsushita K; Ballantyne CM; Inker LA; Coresh J
Am J Kidney Dis; 2012 May; 59(5):653-62. PubMed ID: 22305758
[TBL] [Abstract][Full Text] [Related]
9. Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality.
Rebholz CM; Grams ME; Matsushita K; Inker LA; Foster MC; Levey AS; Selvin E; Coresh J
Clin J Am Soc Nephrol; 2015 Jun; 10(6):941-8. PubMed ID: 25825481
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes.
Schöttker B; Herder C; Müller H; Brenner H; Rothenbacher D
Diabetes Care; 2012 Apr; 35(4):879-86. PubMed ID: 22338108
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease in older people; disease or dilemma?
Ahmed AK; Brown SH; Abdelhafiz AH
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):835-41. PubMed ID: 20814116
[TBL] [Abstract][Full Text] [Related]
12. The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: An external validation and clinical impact projection cohort study.
Major RW; Shepherd D; Medcalf JF; Xu G; Gray LJ; Brunskill NJ
PLoS Med; 2019 Nov; 16(11):e1002955. PubMed ID: 31693662
[TBL] [Abstract][Full Text] [Related]
13. [Early diagnosis of chronic kidney disease. New insights into creatinine and proteinuria].
Brandenburg V; Floege J
Med Klin (Munich); 2006 Mar; 101 Suppl 1():158-62. PubMed ID: 16802544
[TBL] [Abstract][Full Text] [Related]
14. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
Desai AS; Toto R; Jarolim P; Uno H; Eckardt KU; Kewalramani R; Levey AS; Lewis EF; McMurray JJ; Parving HH; Solomon SD; Pfeffer MA
Am J Kidney Dis; 2011 Nov; 58(5):717-28. PubMed ID: 21820220
[TBL] [Abstract][Full Text] [Related]
15. Predicting initiation and progression of chronic kidney disease: Developing renal risk scores.
Taal MW; Brenner BM
Kidney Int; 2006 Nov; 70(10):1694-705. PubMed ID: 16969387
[TBL] [Abstract][Full Text] [Related]
16. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.
Bolignano D; Lacquaniti A; Coppolino G; Donato V; Campo S; Fazio MR; Nicocia G; Buemi M
Clin J Am Soc Nephrol; 2009 Feb; 4(2):337-44. PubMed ID: 19176795
[TBL] [Abstract][Full Text] [Related]
18. Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome.
Satoh-Asahara N; Suganami T; Majima T; Kotani K; Kato Y; Araki R; Koyama K; Okajima T; Tanabe M; Oishi M; Himeno A; Kono S; Sugawara A; Hattori M; Ogawa Y; Shimatsu A;
Clin J Am Soc Nephrol; 2011 Feb; 6(2):265-73. PubMed ID: 21051748
[TBL] [Abstract][Full Text] [Related]
19. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
